Literature DB >> 15037304

The good, the bad and the ugly: the practical consequences of centrosome amplification.

Greenfield Sluder1, Joshua J Nordberg.   

Abstract

Centrosome amplification (the presence of more than two centrosomes at mitosis) is characteristic of many human cancers. Extra centrosomes can cause the assembly of multipolar spindles, which unequally distribute chromosomes to daughter cells; the resulting genetic imbalances may contribute to cellular transformation. However, this raises the question of how a population of cells with centrosome amplification can survive such chaotic mitoses without soon becoming non-viable as a result of chromosome loss. Recent observations indicate that a variety of mechanisms partially mute the practical consequences of centrosome amplification. Consequently, populations of cells propagate with good efficiency, despite centrosome amplification, yet have an elevated mitotic error rate that can fuel the evolution of the transformed state.

Entities:  

Mesh:

Year:  2004        PMID: 15037304     DOI: 10.1016/j.ceb.2003.11.006

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  52 in total

1.  Centrosome biogenesis continues in the absence of microtubules during prolonged S-phase arrest.

Authors:  Elizabeth S Collins; Jessica E Hornick; Thomas M Durcan; Nicholas S Collins; William Archer; Kul B Karanjeet; Kevin T Vaughan; Edward H Hinchcliffe
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 2.  Such small hands: the roles of centrins/caltractins in the centriole and in genome maintenance.

Authors:  Tiago J Dantas; Owen M Daly; Ciaran G Morrison
Journal:  Cell Mol Life Sci       Date:  2012-03-30       Impact factor: 9.261

3.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

4.  Centrosome duplication proceeds during mimosine-induced G1 cell cycle arrest.

Authors:  Thomas M Durcan; Elizabeth S Halpin; Luciana Casaletti; Kevin T Vaughan; Maggie R Pierson; Shane Woods; Edward H Hinchcliffe
Journal:  J Cell Physiol       Date:  2008-04       Impact factor: 6.384

5.  Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints.

Authors:  Stephan C Jahn; Patrick E Corsino; Bradley J Davis; Mary E Law; Peter Nørgaard; Brian K Law
Journal:  J Cell Sci       Date:  2013-01-15       Impact factor: 5.285

6.  RINT-1 serves as a tumor suppressor and maintains Golgi dynamics and centrosome integrity for cell survival.

Authors:  Xiaoqin Lin; Chang-Ching Liu; Qing Gao; Xiaohai Zhang; GuiKai Wu; Wen-Hwa Lee
Journal:  Mol Cell Biol       Date:  2007-04-30       Impact factor: 4.272

7.  PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen.

Authors:  S Kotadia; L R Kao; S A Comerford; R T Jones; R E Hammer; T L Megraw
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

8.  Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes.

Authors:  Mijung Kwon; Susana A Godinho; Namrata S Chandhok; Neil J Ganem; Ammar Azioune; Manuel Thery; David Pellman
Journal:  Genes Dev       Date:  2008-07-28       Impact factor: 11.361

Review 9.  MdmX regulates transformation and chromosomal stability in p53-deficient cells.

Authors:  Zdenka Matijasevic; Anna Krzywicka-Racka; Greenfield Sluder; Stephen N Jones
Journal:  Cell Cycle       Date:  2008-10-15       Impact factor: 4.534

10.  Association of loss of BRCA1 expression with centrosome aberration in human breast cancer.

Authors:  Atsushi Shimomura; Yasuo Miyoshi; Tetsuya Taguchi; Yasuhiro Tamaki; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.